Group 1 - The Hong Kong stock market saw a strong performance in innovative pharmaceutical stocks, with CSPC Pharmaceutical Group rising over 7%, Kelun-Bio increasing more than 6%, and Innovent Biologics up over 5% [1] - The related ETFs for innovative pharmaceuticals in Hong Kong experienced gains of over 3% [1] Group 2 - Multiple investment opportunities are present in the current healthcare sector, driven by the recovery of overseas orders and domestic capacity clearance in the CXO industry, leading to sustained improvement in market conditions and potential for valuation recovery [2] - The medical device sector benefits from domestic equipment upgrade policies and expansion into overseas markets, with continuous catalysts in cutting-edge areas such as brain-computer interfaces and AI imaging [2] - Internet healthcare is seeing improved operational efficiency and clearer profit growth trajectories amid deepening reforms in medical insurance payment systems [2]
港股创新药概念股走强，港股创新药相关ETF涨超3%
Mei Ri Jing Ji Xin Wen·2026-02-10 03:08